University of California, San Francisco
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).
University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.
University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,713 total, page 3 of 35
Comparison of Whole Body DWI to FDG PET
NCT06630845
Skin Barrier Function and Inflammation in Aging: The BIA Study
NCT06750653
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
NCT06495593
Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy
NCT07147166
Polymer Induced Liquid Precursor (PILP) in Adults in With Dentin Caries
NCT06727110
CirrhosisRx CDS System
NCT05967273
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
NCT06504381
Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder
NCT06518785
Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT
NCT06633224
Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
NCT06557512
Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine
NCT05962229
CONNECTing to LungCare
NCT06213532
Effect of Exercise on Body Composition and Bone Health in Patients With Thalassemia
NCT07064941
Feasibility of HPV Testing With Mail-delivered Sample Collection Kits
NCT07087145
Achieving Chronic Care equiTy by leVeraging the Telehealth Ecosystem
NCT06598436
Treating Major Depression With Yoga Mono-therapy
NCT06091527
Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP
NCT06414408
Device Use Reimagined Through Education And Mentorship
NCT06546930
Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma
NCT06606028
Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms
NCT02638701
Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
NCT06600906
Ultrasound Neuromodulation in Essential Tremor
NCT06610877
Two-fraction HDR Monotherapy for Localized Prostate Cancer
NCT05665738
Studying the Effects of Digital Interventions on Cognition, Wellbeing, Stress, and Sleep in Older Adults
NCT06633978
A Single Arm Study of Extracorporeal Shockwave Therapy for Management of Erectile Dysfunction
NCT07592533
Improving Congenital Heart Disease Care
NCT06581484
Lung and Heart Function Across Decades of Life in Health
NCT07641413
Prescription of Letrozole for Uterine Myoma
NCT06143631
Group-based Integrative Pain Management in Primary Care Safety Net Clinics
NCT06327542
Smoke-free Home Study in Subsidized Housing
NCT06170437
Exploring Clinical Utility of Wearables for the Bladder in Pelvic Health Physical Therapy Clinics
NCT07451106
Mechanistic Insights From Bronchoscopy Airway Samples
NCT06105710
Open-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis
NCT06365892
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
NCT06252675
Platelet Rich Plasma Injections In Young And Old Human Subjects
NCT06451120
PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
NCT06401707
Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)
NCT06215469
Multidisciplinary Low-Barrier and Mobile HIV Care to Improve Retention and Viral Suppression: Stakeholder-Engaged Design and Evaluation
NCT05887557
Cultural Adaptation of Drug Treatment for DJJ Youth
NCT06003725
A Primary Care Based Intervention to Prevent Childhood Obesity Among Low-income Latino Children
NCT06398509
Precision Dosing of Metformin in Youth With T2D
NCT06120881
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
NCT06152653
Patient-centered Information on Permanent Contraception
NCT06296797
Enhancing Attention and Wellbeing Using Digital Therapeutics
NCT06397469
Levothyroxine Supplementation for Heart Transplant Recipients
NCT06428097
Cerebellar Deep Brain Stimulation for Movement Disorders in Cerebral Palsy in Children and Young Adults
NCT06122675
Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs
NCT06179498
Better Sleep Study
NCT06139861
Advance Care Planning With Formerly Homeless Older Adults Residing in Permanent Supportive Housing
NCT06239896
HEalth Advocate for Liver Transplantation: Improving Transition of Care for Adolescent Liver Transplant Recipients
NCT06386198
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 193 |
| Phase 2 | 166 |
| Phase 3 | 44 |
| Phase 4 | 152 |
Therapeutic Areas
What is open in the University of California, San Francisco pipeline
272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).
Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, San Francisco: open-pipeline peers nationwide
Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,713 trials (± recruiting share)
- Duke University · 1,725 trials · 11% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- Youngstown State University · 16% recruiting · 19 trials
- ECOG-ACRIN Cancer Research Group · 16% recruiting · 75 trials
Related
What to do with this University of California, San Francisco page
1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.
- 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets.Report a data error.